SCHEMBL682272

SCHEMBL682272

C=C1CC(C(C)(C)C)CC(=O)N1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.38
MAP3K14 Q99558 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15187637 0.84 CRBN (0.52) CRBNMAP3K14
SCHEMBL13934537 0.68 CRBN (0.30) CRBN
SCHEMBL9976654 0.68 CRBN (0.39) CRBNMAP3K14
SCHEMBL14592897 0.67 ALDH1A1 (0.34) CRBN
SCHEMBL8931418 0.67 ALDH1A1 (0.34) CRBN
SCHEMBL14592820 0.67 ALDH1A1 (0.34) CRBN
SCHEMBL24111080 0.67 CRBN (0.48) CRBNMAP3K14
SCHEMBL23351180 0.67
SCHEMBL2691341 0.66
SCHEMBL14528088 0.65 CRBN (0.37) CRBNMAP3K14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957056-B2 Migrastatin analogs in the treatment of cancer SLOAN-KETTERING INSTIUTE FOR CANCER RESEARCH (US) 2015-02-17 US disclosed
US-8188141-B2 Isomigrastatin analogs in the treatment of cancer SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-05-29 US disclosed
US-20110281916-A1 MIGRASTATIN ANALOGS AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-11-17 US disclosed
US-7943800-B2 Migrastatin analogs and uses thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2011-05-17 US disclosed
US-20090124662-A1 Migrastatin analogs in the treatment of cancer SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2009-05-14 US disclosed
US-20090054488-A1 Isomigrastatin Analogs In The Treatment Of Cancer NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-02-26 US disclosed
US-20070037852-A1 Migrastatin analogs and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054488-A1 Isomigrastatin Analogs In The Treatment Of Cancer EDNRB, KDR, IGF1R CRBN 2678/4885MAP3K14 2684/4885
US-20090124662-A1 Migrastatin analogs in the treatment of cancer MTX1, MTNR1B, MTNR1A CRBN 3295/4885MAP3K14 3123/4885
US-20110281916-A1 MIGRASTATIN ANALOGS AND USES THEREOF KDR, HMGCR, LPAR3 CRBN 2072/4885MAP3K14 3198/4885
US-20070037852-A1 Migrastatin analogs and uses thereof KDR, MTX1, FOXM1 CRBN 2312/4885MAP3K14 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.